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ABSTRACT
In total, 438 (1.7%) Escherichia coli and 125 (3.98%) Klebsiella pneumoniae isolates were found to be
producers of extended-spectrum b-lactamase (ESBL) during 1995–2003 in southern Spain. There was a
significant increase in the frequency of ESBL-producing E. coli isolates, from < 0.36% before 1999 to 4.8%
in 2003, while the frequency of ESBL-producing K. pneumoniae isolates decreased during the same
period. The most common ESBLs detected in K. pneumoniae were SHV type, whereas both CTX-M and
SHV types were detected in E. coli. In addition, E. coli isolates showed greater clonal diversity (84 distinct
REP-PCR patterns, compared with five in K. pneumoniae), fewer enzymes per isolate, and a higher
number of isolates recovered from outpatients. These differences may have implications for the control
measures that should be used for these two microorganisms.
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INTRODUCTION
Resistance to b-lactams in Enterobacteriaceae,
associated with plasmid-mediated extended-
spectrum b-lactamases (ESBLs), has become a
worldwide problem [1,2]. ESBLs confer clinically
significant resistance to broad-spectrum penicil-
lins, monobactams and cephalosporins (except
cephamycins), and are often associated with
resistance to other non-related antibiotics in
multiresistant pathogens [3]. The first ESBLs
were reported in Klebsiella pneumoniae in
1983 [4], and ESBLs spread subsequently to
Escherichia coli and, occasionally, other Entero-
bacteriaceae. However, Klebsiella spp. and E. coli
continue to be the two most important organ-
isms associated with ESBL-mediated resistance.
ESBLs have been classified into types, based on
their deduced amino-acid sequences (i.e., the
TEM, SHV, CTX-M, PER, VEB, GES, TLA, BES
and OXA types). TEM or SHV derivatives have
been the most prevalent types of ESBL, but the
prevalence of the CTX-M type has increased
dramatically since 1995 in most parts of the
world, including Europe, Asia, South America
[1,5] and North America [6].
The epidemiology of ESBL-producing isolates
of K. pneumoniae has been studied extensively.
Such isolates are involved frequently in out-
breaks of infection, particularly in high-risk areas,
such as intensive care or neonatal units. Out-
breaks involving spread between hospitals [7]
and long-term care centres [8] have also been
described. Although there are numerous reports
describing the spread and epidemiology of ESBL-
producing K. pneumoniae, the behaviour of ESBL-
producing E. coli is less well-known. To date, few
outbreaks caused by a single ESBL-producing
E. coli strain [9–12], or involving nosocomial
spread of plasmids between ESBL-producing
K. pneumoniae and ESBL-producing E. coli strains
[8,13], have been described. However, recent
studies have suggested that ESBL-producing
Corresponding author and reprint requests: L. Romero,
Departamento de Microbiologı´a, Hospital Virgen Macarena,
Dr Fedriani s ⁄n, Sevilla 41009, Spain
E-mail: lromeroperez@us.es
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
isolates of E. coli have begun to spread in
community settings [14–16].
Despite the emergence of the CTX-M type, the
impact of these new enzymes on the local preval-
ence of ESBL-producing Enterobacteriaceae in a
specific region has been neither analysed nor
compared with that of other ESBLs. Longitudinal
descriptions over a long period in a single area are
limited and have dealt mostly with K. pneumoniae
isolates from inpatients [17]. For E. coli, most
reports describe only periods of 1–2 years [16], or
are focused on the production of one particular
ESBL [18]. Although there are several previous
reports highlighting the increasing prevalence of
ESBL-producing isolates of E. coli and K. pneumo-
niae [1,2], no comparative analyses of the two
species have been described. Therefore, the aims of
the present study were: (1) to describe the epide-
miological evolution of ESBL-producing E. coli and
K. pneumoniae isolates, in the context of the world-
wide spread of CTX-M, during a 9-year period;
(2) to determine the epidemiological relationship
between isolates and the types of enzyme pro-
duced; and (3) to determine the differential char-
acteristics of the two species involved.
MATERIALS AND METHODS
Setting
The study was carried out in the area served by the University
Hospital Virgen Macarena, located in the north of Seville
(Spain). The Clinical Microbiology Laboratory receives
samples from the 1000-bed hospital, the outpatient clinic, a
nearby chronic-care hospital, and the primary-care services of
an area with 500 000 inhabitants.
Isolates
During the period January 1995 to December 2003, all E. coli and
Klebsiella spp. isolates from significant clinical samples were
analysed for ESBL production. From 1995 until 2000, identifica-
tion and preliminary antimicrobial susceptibilities were deter-
mined by the MicroScan system (Dade Behring, Sacramento,
CA, USA), and from 2001 until 2003, by the VITEK2 system
(bioMe´rieux; Hazelwood, MO, USA). Samples referred from
primary-care services, the outpatient clinic and the emergency
department were considered to come from non-hospitalised
patients, while those referred from hospital wards were
considered to come from hospitalised patients. Differences in
proportions among categorical data were calculated by the
chi-square test, with p < 0.05 considered to be significant.
Screening for ESBL producers
All isolates with a cefpodoxime MIC ‡ 8 mg ⁄L and ⁄ or a
cefotaxime ⁄ ceftazidime MIC ‡ 2 mg ⁄L with the automated
methods were tested for ESBL production according to NCCLS
criteria [19]. ESBL production was tested by the disk-diffusion
method using Mueller–Hinton agar plates (Becton Dickinson,
Le Point de Claix, France) and disks containing 30 lg of
cefotaxime or ceftazidime, with or without 10 lg of clavulanic
acid, and 10 lg of cefpodoxime, with or without 1 lg of
clavulanic acid, according to the manufacturer’s instructions.
ESBL production was confirmed by the NCCLS microdilution
technique [19]. A two-fold decrease in MIC of ‡ 3 mg ⁄L for
either ceftazidime, cefotaxime or cefpodoxime when tested in
combination with 4 mg ⁄L of clavulanic acid, compared with
the MIC when tested alone, was considered indicative of ESBL
production [19].
Antimicrobial agent susceptibility assays
The activities of ceftazidime, cefotaxime, cefoxitin,
ciprofloxacin, gentamicin, amikacin, amoxycillin–clavunalate,
piperacillin–tazobactam, imipenem and trimethoprim–sulpha-
methoxazole were determined by microdilution assay
according to NCCLS guidelines [20,21]. E. coli ATCC 25922,
E. coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853 and
K. pneumoniae ATCC 700603 were used as control strains.
Molecular typing
Clonal relationships were determined by REP-PCR using
primers REP-1 (5¢-IIIGCGCCGICATCAGGC-3¢) and REP-2
(5¢-ACGTCTTATCAGGCCTAC-3¢) [22] for isolates collected
between 1995 and 2001. DNA was extracted by boiling a
suspension of a colony at 100C for 10 min. The supernatant
from this suspension (24.5 lL) was used as the PCR template.
All reactions were performed in a 50 lL-volume, using 2 U of
Taq DNA polymerase (Invitrogen, Barcelona, Spain). Cycling
conditions comprised 94C for 3 min, followed by 30 cycles of
94C for 1 min, 40C for 1 min, and 65C for 8 min, with a final
extension at 65C for 8 min. DNA band patterns were analysed
visually following electrophoresis on agarose 1.5% w ⁄v gels.
Two isolates were considered to be clonally related when the
number of DNA bands and their positions matched.
b-Lactamase characterisation
Isoelectric focusing and PCR were used for preliminary
characterisation of the b-lactamases produced and their
respective bla genes. Isoelectric focusing (PhastGel IEF 3-9;
Pharmacia, Barcelona, Spain) was performed to identify the
numbers and isoelectric points (pI) of the b-lactamases present.
The focused b-lactamases were detected by overlaying the gel
with nitrocefin (0.5 mg ⁄mL) [23–25]. Known producers of
TEM-1, TEM-24, SHV-2 and CTX-M-9 b-lactamases were
included as controls.
The presence of bla genes was detected with oligonucleotide
primers designed to amplify the most common subgroups
within the ESBL family: blaTEM [26], blaSHV [26], blaCTX-M-10 [27]
and blaCTX-M-9 [28]. The primers used for each individual
isolate were selected according to the isoelectric focusing
results, namely pI 4.5–6.5 for blaTEM, and pI 7.0–8.2 for blaSHV
and blaCTX. All reactions were performed in 25-lL volumes
with 2 U of FastStart Polymerase (Roche Diagnostics, Mann-
heim, Germany). Cycling parameters comprised 95C for
4 min, followed by 35 cycles of 95C for 30 s, 58C for 30 s
for TEM and SHV, 62C for 30 s for CTX-M-9 or 60C for 30 s
for CTX-M-10, and 72C for 1 min, with a final extension at
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72C for 7 min. Positive controls were strains of E. coli
containing either the blaTEM-1, blaTEM-3, blaSHV-1, blaSHV-5,
blaCTX-M-9 or blaCTX-M-10 genes, with E. coli J53 Rif-R as a
negative control.
Amplicons were sequenced by CSIC (Madrid, Spain),
equipped with an ABI PRISM 377 sequencer (Applied Biosys-
tems, Foster City, USA). Sequences were analysed with the
Chromas application and the BLAST (http://www.ncbi.nlm.-
nih.gov/BLAST) and Traduction Multiple (Infobiogen; http://
www.Infobiogen.fr/services/analyzeq/cgi-bin/traduc-in.pl)
algorithms.
RESULTS
In total, 25 447 E. coli and 2790 K. pneumoniae
isolates were recovered during 1995–2003. ESBL
production was detected in 438 (1.7%) E. coli
isolates recovered from 438 patients, and in 125
(3.98%) K. pneumoniae isolates from 122 patients.
The median age of patients infected with an
ESBL-producing isolate was 67 years (range 0–
89 years), and a higher proportion of female
patients was infected with ESBL-producing
E. coli than with ESBL-producing K. pneumoniae
(69% vs. 44%; p 0.0003). The ESBL-producing
E. coli and K. pneumoniae isolates were recovered
from the following specimens: urine, 70% and
54% (p 0.004); blood, 9% and 14% (p 0.2);
wounds, 13% and 11% (p 0.6); abscesses, 4%
and 6% (p 0.5); respiratory tract, 1% and 9%
(p 0.009); and others (catheter, faeces and biop-
sies), 3% and 6% (p 0.3), respectively.
By the microdilution method, all ESBL-produ-
cing E. coli and K. pneumoniae isolates were
susceptible to carbapenems, and showed similar
rates of susceptibility to amikacin (91% and 94%;
p 0.4), gentamicin (60% and 64%; p 0.5), amoxy-
cillin–clavulanate (69% and 61%; p 0.2) and
trimethoprim–sulphamethoxazole (38% and
40%; p 0.7). However, susceptibility rates differed
between these microorganisms for piperacillin–
tazobactam (75% of ESBL-producing E. coli and
52% of ESBL-producing K. pneumoniae; p 0.0001)
and ciprofloxacin (17% of ESBL-producing E. coli
and 50% of ESBL-producing K. pneumoniae;
p < 0.0001).
During the study period, the annual distribu-
tion of ESBL-producing microorganisms was dif-
ferent for E. coli and K. pneumoniae. From 1995 to
1998, the absolute number of ESBL-producing
E. coli isolates was less than seven per annum.
After 1999, a steady increase was observed,
reaching 139 isolates in 2003. In contrast, the
annual number of ESBL-producing K. pneumoniae
isolates decreased gradually from 34 in 1995 to
nine in 2003. Similarly, the frequency of ESBL-
producing E. coli isolates also increased gradually,
from 0.31% in 1995 to 4.8% in 2003, while the
frequency of ESBL-producing K. pneumoniae iso-
lates decreased. The median frequency of ESBL-
producing K. pneumoniae isolates in the period
1995–1997 was 7.2% (range, 5.2–9.7%), compared
with 2.5% (range, 1.7–3.2%) in the period 1998–
2003.
The ESBL-producing isolates of E. coli and
K. pneumoniae were from non-hospitalised
patients in 64% and 36% of the cases, respect-
ively (p < 0.0001). The annual distributions for
both microorganisms according to origin are
shown in Fig. 1. The increase in ESBL-producing
E. coli occurred almost simultaneously in non-
hospitalised and hospitalised patients, although
the increase was observed in inpatients a year
earlier.
Fig. 1. Comparison of the frequency of extended-spectrum
b-lactamase (ESBL)-producing Escherichia coli and
Klebsiella pneumoniae according to origin. (a) Frequency of
ESBL-producing E. coli from inpatients and outpatients.
(b) Frequency of ESBL-producing K. pneumoniae from
inpatients and outpatients.
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All ESBL producers (n = 415) isolated during
1995–2002 were examined by isoelectric focusing
and PCR for the presence of the blaCTX-M, blaTEM
and blaSHV genes. All b-lactamase bands with a pI
that might correspond to TEM-1, TEM-2 or SHV-
1 were excluded from the analysis. Multiple
b-lactamase genes were identified in 53 (17%)
ESBL-producing E. coli isolates (48 with two
genes; five with three genes) and in 59 (51%)
ESBL-producing K. pneumoniae isolates (Tables 1
and 2). SHV enzymes were the most common
ESBLs detected in K. pneumoniae (97% of the
isolates) (Table 2), whereas CTX-M and SHV
enzymes were the most common types in E. coli,
and were observed at similar frequencies (46%
and 44%, respectively; Table 1). During 1995–
1998, the rare ESBL-producing E. coli isolates were
predominantly SHV producers, while the increase
in the total percentage of ESBL-producing E. coli
isolates from 1999 was associated with isolates
producing any of the three types of ESBL. How-
ever, the relative frequency of isolates producing
CTX-M-type enzymes tended to increase, while
that of those producing SHV tended to decrease
(Table 1). In contrast, all K. pneumoniae isolates
produced SHV-type enzymes during 1995–2000,
often in combination with TEM-type enzymes,
but a few CTX-M-producing K. pneumoniae iso-
lates began to appear during 2001 and 2002
(Table 2).
In total, 262 (48%) bla genes were sequenced, of
which 68% encoded CTX-M enzymes (100 (97%)
CTX-M-14 and three (3%) CTX-M-9), 56% enco-
ded SHV enzymes (112 (80.5%) SHV-12, 25 (18%)
SHV-4, and two (1.5%) SHV-2a), and 14% enco-
ded TEM enzymes (ten (50%) TEM-4, eight (40%)
TEM-20, and two (10%) TEM-53).
The clonal relationships of all ESBL-produ-
cing isolates detected from January 1995 to June
2001 (119 E. coli and 103 K. pneumoniae) were
evaluated by REP-PCR. For the 119 ESBL-pro-
ducing E. coli isolates, 84 distinct REP-PCR
patterns were obtained, distributed in 69 non-
related patterns and 15 clonally related groups.
There was great variability in the different
genotypes of E. coli, with a median of 2–5
different bands among the most related isolates.
During the total period, 13 clonal groups of 2–4
isolates were observed, with two larger groups
(seven and nine isolates, respectively) during
the 2000–2001 period. The largest group com-
prised isolates from inpatients in the long-term
care hospital, and the other clonally related
ESBL-producing E. coli groups also comprised
isolates mainly (63.4%) from hospitalised
patients. In contrast, ESBL-producing K. pneu-
moniae isolates were more related, with the 103
isolates belonging to only five clonally related
groups, of which one predominated (containing
92 isolates from different wards throughout the
total study period).
DISCUSSION
ESBL-producing Enterobacteriaceae are among
the most problematic multiresistant bacteria
worldwide and are being isolated with increased
frequency [2,29–31]. Most isolates are recovered
from hospitalised patients, but recent data indi-
cate an increasing problem in nursing homes and
in the community [16,31]. Such surveys usually
describe a transient situation for an institution or
region at a certain time-point, and it is difficult to
gain an overview of the general situation regard-
ing the main ESBL-producing organisms.
Table 1. Annual distribution of extended-spectrum b-lac-
tamase types in Escherichia coli
Year
No. of
isolates
Type of b-lactamase
No. of enzymes
per isolateTEM SHV CTX-M
n % n % n % 1 2 3
1995 7 0 0 7 100 0 0 7 0 0
1996 1 0 0 1 100 0 0 1 0 0
1997 3 1 33 3 100 0 0 2 1 0
1998 2 1 50 1 50 0 0 2 0 0
1999 13 6 46 10 77 3 23 7 6 0
2000 53 24 45 28 53 23 43 32 20 1
2001 106 42 38 43 40 42 40 87 17 2
2002 114 12 10 40 33 70 61 108 4 2
Total 299 86 27 133 44 138 46 246 48 5
Table 2. Annual distribution of extended-spectrum b-lac-
tamase types in Klebsiella pneumoniae
Year
No. of
isolates
Type of b-lactamase
No. of enzymes
per isolateTEM SHV CTX-M
n % n % n % 1 2 3
1995 34 2 6 34 100 0 0 32 2 0
1996 18 14 78 18 100 0 0 4 14 0
1997 21 15 71 21 100 0 0 6 15 0
1998 12 10 83 12 100 1 8 1 11 0
1999 9 7 78 9 100 0 0 2 7 0
2000 5 4 80 5 100 0 0 1 4 0
2001 8 2 25 8 100 1 12 5 3 0
2002 9 3 33 6 66 3 33 6 3 0
Total 116 57 49 113 97 5 4 57 59 0
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The present study offers a view of the dynamic
evolution of the two most significant ESBL-produ-
cing organisms, with isolates from both hospital-
ised and non-hospitalised patients. The results
show an important increase in the frequency of
ESBL-producing E. coli isolates in this area of Spain,
beginning in 1999, confirming the impression that
this organism is an emerging multiresistant patho-
gen. During 1999, the isolation of ESBL-producing
E. coli strains found in the SENTRY project was 3.3–
8.5% in Latin America [29], with an even higher
frequency of 23.6% reported from China [32],
compared with a very low frequency of 0.25%
reported from Canada in 1999–2000 [12]. The final
3 years of the present study found a median
incidence of 24 cases ⁄ 100 000 population ⁄year,
which is significantly higher than that recorded in
the Calgary region (5.5 ⁄ 100 000 inhabitants ⁄ year)
during the same period, including both inpatients
and outpatients [16]. In contrast, the overall ESBL-
producing K. pneumoniae prevalence (3.8%) was
lower than in previous studies [2,29]. The
decreased isolation frequency of ESBL-producing
K. pneumoniae observed during the last 6 years
could be related to the strict and successful infec-
tion control measures introduced in this institution
to control methicillin-resistant Staphylococcus aure-
us and multiresistant Acinetobacter baumannii [33].
Based on the origin of the isolates, ESBL-
producing E. coli and K. pneumoniae seem to show
different kinds of epidemiological behaviour.
While ESBL-producing K. pneumoniae has been,
and still is, mainly a nosocomial pathogen, ESBL-
producing E. coli is also emerging as an important
pathogen in outpatients [16]. The ESBL-producing
E. coli isolates from non-hospitalised patients
emerged a year after the observed increase in
the number of isolates from hospital wards, but
there was subsequent parallel development. Pre-
vious hospitalisation was identified as one of the
main risk-factors for ESBL-producing E. coli
infections in non-hospitalised patients [15], and
this could partly explain the emergence of these
strains in non-hospitalised patients after a delay
of 1 year. However, these data should not lead to
an assumption that the emergence of ESBL-pro-
ducing E. coli in the community proceeds mainly
from the dissemination of hospital strains. Some
patients might have acquired ESBL-producing
E. coli in the community, but then developed
infections caused by these organisms following
hospital admission, since hospitalised patients
more frequently have risk-factors (antimicrobial
use, debilitating underlying diseases, invasive
procedures) for infection with multiresistant
organisms. Of concern was the fact that E. coli
isolates were more frequently ciprofloxacin-resist-
ant than were K. pneumoniae isolates. This asso-
ciation, which has also been observed previously
by Tolun et al. [34], has not been explained,
although previous fluoroquinolone treatment
has been identified as a risk-factor for ESBL-
producing E. coli infection in non-hospitalised
patients [15].
Another characteristic differentiating between
ESBL-producing E. coli and K. pneumoniae isolates
was the number of clonally related groups found
during the study period. The emergence in our
area of ESBL-producing E. coli since 1999 was
caused mainly by genetically unrelated isolates.
This phenomenon has been observed previously
in isolates from an intensive care unit [32] and
from the community [14]. Although E. coli is
associated less frequently with clonal dissemin-
ation, the small group of nine strains isolated in
the long-term care hospital was an interesting
observation, reflecting reports of small groups of
ESBL-producing E. coli in different Russian hos-
pitals [18], and the transmission of an epidemic
strain in three geriatric hospitals [9]. In contrast,
ESBL-producing K. pneumoniae isolates were more
genetically related, with the endemic persistence
of one of the five REP-PCR genotypes. Similar
results, with a large number of isolates in each
cluster, were obtained in a previous 1-year ana-
lysis of strains from an intensive care unit [32].
The number of isolates producing multiple
b-lactamases was much higher among K. pneu-
monia than among E. coli, but was similar to that
found in a previous survey [32]. The most
frequent type of ESBL in K. pneumoniae in the
present study was SHV, compared with SHV and
CTX-M in E. coli. TEM has been reported to be
more prevalent in E. coli in some surveys [32], and
CTX-M in others [35], while a clear predominance
has not been found in K. pneumoniae [17,32,36]. In
our area, the CTX-M-producing E. coli isolates
emerged in 1999, and have gradually become
more prevalent. This agrees with the increased
frequencies of CTX-M-producing bacteria in re-
ports from Europe, North and South America,
Africa and Asia [1,5].
In summary, these results demonstrate the
emergence of ESBL-producing E. coli in the
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context of increasing control over ESBL-produ-
cing K. pneumoniae. The present data also indicate
that the epidemiologies of these two species show
substantial differences, in that ESBL-producing
E. coli strains were isolated from hospitalised and
non-hospitalised patients, produced different
types of ESBLs and were clonally diverse, while
ESBL-producing K. pneumoniae strains were iso-
lated mainly from hospitalised patients, produced
predominantly SHV-type enzymes and tended to
be clonally related. These epidemiological char-
acteristics are shared with other ESBL-producing
enterobacteria, such as Enterobacter aerogenes and
Proteus mirabilis, which are detected increasingly
in France [37], Belgium [38] and Italy [39,40].
These differences may have implications for the
underlying rationale of the control measures used
for these microorganisms. In the period of analy-
sis, except for well-defined cases, there was no
real epidemic or endemic problem, but, rather, an
‘allodemic situation’, to use the term proposed by
Baquero et al. [41].
The present study had some limitations, in that
the clinical aspects were not considered, the
colonisation rate in the community was not
known, and plasmid analysis was not performed.
Several issues remain unresolved, including the
question as to whether dissemination of a plasmid
or transposable element was involved, or whether
these observations result from the evolutionary
success of a particular enzyme (CTX-M type vs.
SHV type). Further investigations are required to
evaluate the impact of antibiotic selection, the
dynamic flow of organisms and genes between
hospital and community, community colonisa-
tion, and the multiple origins of isolates. On the
basis of these data, different interventions to
control host-to-host spread should be designed
which take into account the fact that the hospital
is not a microbiologically separate entity from the
rest of the care system.
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